Welcome to our dedicated page for Mesa Laboratories news (Ticker: MLAB), a resource for investors and traders seeking the latest updates and insights on Mesa Laboratories stock.
Mesa Laboratories designs and manufactures life science tools and critical quality control solutions for regulated pharmaceutical, healthcare and medical device applications. The company reports through Sterilization and Disinfection Control, Biopharmaceutical Development, Calibration Solutions and Clinical Genomics, covering indicators for sterilization and cleaning processes, protein analysis and peptide synthesis systems, calibration products and genetic analysis tools.
Recurring company news includes quarterly and fiscal-year results, segment performance commentary, regular cash dividend declarations, investor conference participation and governance updates such as leadership transitions. Updates often connect Mesa's product mix, end-market conditions, debt management and operating margins with demand from regulated life sciences customers.
Mesa Laboratories (NASDAQ:MLAB) reported first fiscal quarter 2027 results for the period ended June 30, 2026. Revenues were $60.1 million, up 1.0% year over year, with non-GAAP organic and core organic revenues growth of 1.0% and 0.4%, respectively. GAAP operating income rose 129% to $7.0 million, while non-GAAP adjusted operating income (“AOI”) increased 16.5% to $15.0 million, or $2.61 per diluted share, and 25.6% of revenues; AOI excluding $0.4 million of unusual items grew 19.5% to $15.4 million.
Net income declined 40.3% to $2.8 million, or $0.49 per diluted share, mainly due to a swing from prior-year nonoperating income to nonoperating expense. By division, organic revenue growth was CS +7.6%, BPD +5.0%, CG -0.1%, and SDC -3.6%. Mesa repaid $8.7 million of debt, reducing its Total Net Leverage Ratio to 1.85, below its 2.0 target.
Mesa Labs (NASDAQ:MLAB) announced it will release financial results for its first fiscal quarter 1Q27, ended June 30, 2026, after market close on Monday, August 10, 2026. The company will host its inaugural earnings conference call the same day at 4:30 p.m. Eastern Time to discuss results and hold a Q&A with analysts.
Investors can join via toll-free phone at 1-877-407-4018, international at 1-201-689-8471, using Conference ID 13761713, or through webcast and Call me™ links provided. A replay will be available for 45 days in the investors section of the Mesa Labs website.
Mesa Labs (NASDAQ:MLAB) declared a regular quarterly dividend of $0.16 per share on its common stock. The dividend is payable on September 15, 2026 to shareholders of record as of August 31, 2026.
Mesa designs and manufactures life science tools and critical quality control solutions for pharmaceutical, healthcare and medical device markets.
Mesa Labs (NASDAQ:MLAB) reported 4Q26 revenues of $63.7M, up 2.6% year-over-year, and FY26 revenues of $249.1M, up 3.4%. FY26 net income was $6.7M, up 440%.
Non-GAAP AOI excluding unusual items rose 11.9% to $63.5M (25.5% margin). Free cash flow was $39.6M, and debt repayment of $14.7M reduced total net leverage to 2.11x. SDC and CS grew, while BPD and CG China declined.
Mesa Laboratories (NASDAQ:MLAB) will release fourth-quarter and full fiscal year 2026 financial results on Wednesday, May 27, 2026 at approximately 6:00 A.M. ET. The company will issue a press release covering results for the quarter and fiscal year ended March 31, 2026.
Mesa Laboratories (NASDAQ:MLAB) declared a regular quarterly dividend of $0.16 per share. The dividend is payable on June 15, 2026 to shareholders of record at the close of business on May 29, 2026. The release includes a standard forward-looking risk disclaimer.
Mesa Laboratories (NASDAQ: MLAB) announced a CEO transition: Gary Owens will step down as President and CEO effective April 12, 2026, and Dr. Siddhartha Kadia will become President and CEO and join the Board effective April 13, 2026.
Dr. Kadia brings prior CEO roles at Calibre Scientific and EAG Laboratories, leadership at Life Technologies overseeing a $2 billion business, and global life-sciences experience. The company emphasized a planned, smooth leadership transition.
Mesa Laboratories (NASDAQ:MLAB) reported 3Q26 results for the quarter ended December 31, 2025. Revenues were $65.126 million, up 3.6% year-over-year (7.2% sequential). AOI excluding unusual items rose to $17.072 million (26.2% of revenues). The company repaid $8.7 million of debt, lowering Total Net Leverage Ratio to 2.62.
Division results: SDC +6.0% organic, BPD +17.5% organic, CS -2.5% organic, CG -7.1% organic (China down ~57%, ~$1.2M).
Mesa Laboratories (NASDAQ:MLAB) declared a regular quarterly dividend of $0.16 per share. The dividend is payable on March 16, 2026 to shareholders of record at the close of business on February 28, 2026. The announcement reaffirms the company’s ongoing dividend program while reiterating standard forward-looking statement caution about risks and uncertainties that could affect future results.
Mesa Labs (NASDAQ:MLAB) announced that Gary Owens, President and CEO, and John Sakys, CFO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026.
The company will deliver a Formal Presentation at 4:30 p.m. Pacific Time. A live webcast will be accessible via the Events & Presentations section of Mesa Labs' Investor Relations website at https://investors.mesalabs.com/, and an archived replay will be available at the same link after the presentation.